Vanda Pharmaceuticals Inc.  

(Public, NASDAQ:VNDA)   Watch this stock  
Find more results for VNDA
15.95
+0.05 (0.31%)
Dec 9 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 15.75 - 16.40
52 week 6.91 - 18.00
Open 16.05
Vol / Avg. 332,423.00/622,819.00
Mkt cap 725.98M
P/E     -
Div/yield     -
EPS -0.75
Shares 43.95M
Beta 1.43
Inst. own 94%
Feb 8, 2017
Q4 2016 Vanda Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 29, 2016
Vanda Pharmaceuticals Inc at Piper Jaffray Healthcare Conference - Webcast
Nov 16, 2016
Vanda Pharmaceuticals Inc at Jefferies Healthcare Conference
Nov 15, 2016
Vanda Pharmaceuticals Inc at Stifel Healthcare Conference
Nov 2, 2016
Q3 2016 Vanda Pharmaceuticals Inc Earnings Call - Webcast
Nov 2, 2016
Q3 2016 Vanda Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -1.12% -36.27%
Operating margin -1.70% -36.56%
EBITD margin - -24.21%
Return on average assets -0.84% -20.72%
Return on average equity -1.38% -27.13%
Employees 118 -
CDP Score - -

Address

2200 Pennsylvania Ave NW Ste 300E
WASHINGTON, DC 20037-1754
United States - Map
+1-202-7343400 (Phone)
+1-202-2961450 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company's product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. The Company offers HETLIOZ (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). The Company offers Fanapt (iloperidone) for the treatment of schizophrenia. Additionally, its distribution partners launched Fanapt in Israel and Mexico. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. It is indicated for the treatment of CNS Disorders.

Officers and directors

H. Thomas Watkins Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Mihael H. Polymeropoulos M.D. President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
James Patrick Kelly Chief Financial Officer, Senior Vice President, Treasurer, Secretary
Age: 49
Bio & Compensation  - Reuters
Richard L Gulino Senior Vice President, General Counsel, Secretary
Bio & Compensation  - Reuters
Paolo Baroldi M.D., Ph.D. Senior Vice President, Chief Medical Officer
Age: 64
Bio & Compensation  - Reuters
Gian Piero Reverberi Senior Vice President, Acting Chief Commercial Officer and European General Manager
Bio & Compensation  - Reuters
Kenneth M. Bate Director
Age: 65
Bio & Compensation  - Reuters
Michael F. Cola Independent Director
Age: 56
Bio & Compensation  - Reuters
Richard W. Dugan Independent Director
Age: 73
Bio & Compensation  - Reuters
Vincent J. Milano Independent Director
Age: 52
Bio & Compensation  - Reuters